New haemophilia drug Inno8 tested in healthy volunteers

NCT ID NCT06649630

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial tested the safety of a new drug called Inno8 in 95 healthy men. Participants received either Inno8 or a placebo by injection or as tablets. The study measured side effects and how the drug moves through the body. Results will help decide if Inno8 should be tested further in people with haemophilia A.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Inno8 (NNC0442-0344 A)
What this could lead to: If this early safety trial succeeds, it could support further development of Inno8 as a potential treatment for haemophilia A.
What could go wrong: This is a very early Phase 1 trial in only 95 healthy men, not people with haemophilia. It is designed only to check safety and dosing, not to prove the drug works. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMOPHILIA A

Contacts and locations

Locations

Charité - Campus Charité Mitte - Charité Research Organisation GmbH

Berlin, 10117, Germany
Charité Research Organisation GmbH

Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.